While BRCA1 mutation carriers have an elevated risk for triple-negative breast cancers (TNBCs), BRCA2 mutation carriers develop breast cancers of different subtypes at a similar frequency to the general population and largely develop HR+ tumours2,40; nevertheless, ~20% of BRCA2-associated tumours are TNBCs41. This evidence concerns the gene BRCA2 and neoplasm.